The role of viral and host genetics in natural history and treatment of chronic HCV infection

被引：23

作者：

Doyle, Joseph S. ^{[1
,2
,3
]}

Hellard, Margaret E. ^{[1
,2
,3
]}

Thompson, Alexander J. ^{[4
,5
,6
,7
]}

机构：

[1] Burnet Inst, Ctr Populat Hlth, Melbourne, Vic 3004, Australia

[2] Alfred Hosp, Infect Dis Unit, Melbourne, Vic, Australia

[3] Monash Univ, Dept Epidemiol & Preventat Med, Melbourne, Vic 3004, Australia

[4] St Vincents Hosp, Dept Gastroenterol & Hepatol, Melbourne, Vic 3065, Australia

[5] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia

[6] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA

[7] Duke Univ, Med Ctr, Dept Gastroenterol, Durham, NC USA

来源：

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY | 2012年 / 26卷 / 04期

基金：

英国医学研究理事会;

关键词：

Hepatitis C virus; Genetics; Genome-wide association; Natural history; Treatment; IL28B; Single nucleotide polymorphism; HEPATITIS-C VIRUS; SUSTAINED VIROLOGICAL RESPONSE; GENOME-WIDE-ASSOCIATION; LIVER FIBROSIS PROGRESSION; INTERFERON-FREE REGIMEN; SENSITIVITY-DETERMINING REGION; INHIBITORY RECEPTOR GENES; TREATMENT-NAIVE PATIENTS; AMINO-ACID SUBSTITUTION; CIRRHOSIS RISK SCORE;

D O I：

10.1016/j.bpg.2012.09.004

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Understanding of the natural history and treatment responsiveness of chronic hepatitis C virus (HCV) infection has evolved rapidly in recent years. Advances in HCV molecular virology and host genetics can now better predict spontaneous clearance and treatment outcomes. HCV genotype is the most important viral factor predicting interferon-alpha treatment responsiveness; HCV-1 subtype is emerging as a key determinant of the efficacy of direct acting antiviral therapy. Genome-wide association studies have recently identified several clinically important host determinants of the outcomes of peginterferon-alpha and ribavirin treatment outcome: IL28B polymorphism is associated with spontaneous clearance and treatment responsiveness; ITPA polymorphism protects against ribavirin-induced anaemia and dose reductions; genetic determinants of liver fibrosis progression rate have been proposed. In this review, we evaluate the role of viral and host genetics in the natural history and treatment outcomes of chronic HCV infection, and consider how this knowledge might help individualize clinical management in the era of DAA therapy. (c) 2012 Elsevier Ltd. All rights reserved.

引用

页码：413 / 427

页数：15

共 113 条

[41] Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection [J].

Jacobson, Ira M. ;

McHutchison, John G. ;

Dusheiko, Geoffrey ;

Di Bisceglie, Adrian M. ;

Reddy, K. Rajender ;

Bzowej, Natalie H. ;

Marcellin, Patrick ;

Muir, Andrew J. ;

Ferenci, Peter ;

Flisiak, Robert ;

George, Jacob ;

Rizzetto, Mario ;

Shouval, Daniel ;

Sola, Ricard ;

Terg, Ruben A. ;

Yoshida, Eric M. ;

Adda, Nathalie ;

Bengtsson, Leif ;

Sankoh, Abdul J. ;

Kieffer, Tara L. ;

George, Shelley ;

Kauffman, Robert S. ;

Zeuzem, Stefan .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (25) :2405-2416

[42] Treatment of acute hepatitis C with interferon alfa-2b [J].

Jaeckel, E ;

Cornberg, M ;

Wedemeyer, H ;

Santantonio, T ;

Mayer, J ;

Zankel, M ;

Pastore, G ;

Dietrich, M ;

Trautwein, C ;

Manns, MP .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (20) :1452-1457

[43] Peginterferon Alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1 [J].

Jeffers, LJ ;

Cassidy, W ;

Howell, CD ;

Hu, S ;

Reddy, KR .

HEPATOLOGY, 2004, 39 (06) :1702-1708

[44] Peginterferon alfa-2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response [J].

Kamal, SM ;

Fouly, AE ;

Kamel, RR ;

Hockenjos, B ;

Al Tawil, A ;

Khalifa, KE ;

He, Q ;

Koziel, MJ ;

El Naggar, KM ;

Rasenack, J ;

Afdhal, NH .

GASTROENTEROLOGY, 2006, 130 (03) :632-638

[45] Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b [J].

Kawaoka, Tomokazu ;

Hayes, C. Nelson ;

Ohishi, Waka ;

Ochi, Hidenori ;

Maekawa, Toshiro ;

Abe, Hiromi ;

Tsuge, Masataka ;

Mitsui, Fukiko ;

Hiraga, Nobuhiko ;

Imamura, Michio ;

Takahashi, Shoichi ;

Kubo, Michaki ;

Tsunoda, Tatsuhiko ;

Nakamura, Yusuke ;

Kumada, Hiromitsu ;

Chayama, Kazuaki .

JOURNAL OF HEPATOLOGY, 2011, 54 (03) :408-414

[46] Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin [J].

Kenny-Walsh, E .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (16) :1228-1233

[47] HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection [J].

Khakoo, SI ;

Thio, CL ;

Martin, MP ;

Brooks, CR ;

Gao, XJ ;

Astemborski, J ;

Cheng, J ;

Goedert, JJ ;

Vlahov, D ;

Hilgartner, M ;

Cox, S ;

Little, AM ;

Alexander, GJ ;

Cramp, ME ;

O'Brien, SJ ;

Rosenberg, WMC ;

Thomas, DL ;

Carrington, M .

SCIENCE, 2004, 305 (5685) :872-874

[48] Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients [J].

Kieffer, Tara L. ;

Sarrazin, Christoph ;

Miller, Janice S. ;

Welker, Martin W. ;

Forestier, Nicole ;

Reesink, Hendrik W. ;

Kwong, Ann D. ;

Zeuzem, Stefan .

HEPATOLOGY, 2007, 46 (03) :631-639

[49] Consistent Beneficial Effects of Killer Cell Immunoglobulin-Like Receptor 2DL3 and Group 1 Human Leukocyte Antigen-C Following Exposure to Hepatitis C Virus [J].

Knapp, Susanne ;

Warshow, Usama ;

Hegazy, Doha ;

Brackenbury, Louise ;

Guha, I. Neil ;

Fowell, Andrew ;

Little, Ann-Margaret ;

Alexander, Graeme J. ;

Rosenberg, William M. C. ;

Cramp, Matthew E. ;

Khakoo, Salim I. .

HEPATOLOGY, 2010, 51 (04) :1168-1175

[50] IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex [J].

Kotenko, SV ;

Gallagher, G ;

Baurin, VV ;

Lewis-Antes, A ;

Shen, ML ;

Shah, NK ;

Langer, JA ;

Sheikh, F ;

Dickensheets, H ;

Donnelly, RP .

NATURE IMMUNOLOGY, 2003, 4 (01) :69-77

← 1 2 3 4 5 6 7 8 9 10 →